Nuvigil or Placebo in Newly Diagnosed Malignant Glioma
Status:
Terminated
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if Nuvigil® improves fatigue experienced by people
receiving external beam radiation therapy for the treatment of malignant gliomas. It is also
being done to determine if Nuvigil® improves cognitive function (perception, thinking,
reasoning, and remembering) and overall quality of life in people receiving external beam
radiation therapy for the treatment of malignant gliomas. Another purpose of this study is to
see if people who receive Nuvigil® have more or less side effects than people who receive
placebo. Placebo is a substance that looks like an active drug but has no active ingredient.
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute